NEW INSIGHTS IN THE DIAGNOSIS AND TREATMENT OF HEART FAILURE
Abstract
Heart failure is a complex and debilitating condition that continues to be a
significant burden on healthcare systems worldwide. This introduction sets the stage
for the subsequent exploration of new insights in the diagnosis and treatment of heart
failure. We will delve into the latest advancements in our understanding of the
pathophysiology of heart failure, the evolving diagnostic tools and techniques, and the
cutting-edge therapeutic options that are reshaping the management of this condition.
By addressing these key areas, we aim to provide a comprehensive overview of the
current landscape in the field of heart failure, offering valuable knowledge and
perspectives for healthcare professionals and researchers. This discussion of new
insights is essential for enhancing patient outcomes, improving quality of life, and
ultimately reducing the global impact of heart failure.
References
F. Nicolini and T. Gherli, “Alternatives to transplantation in the surgical therapy
for heart failure,” European Journal of CardioThoracic Surgery, vol. 35, no. 2, pp.
–228, 2009.
G. Agnetti, C. Husberg, and J. E. van Eyk, “Divide and Conquer: the application of
organelle proteomics to heart failure,” Circulation Research, vol. 108, no. 4, pp.
–526, 2011.
P. Randell, “It’s a MALDI but it’s a goodie: Maldi-Tof mass spectrometry for
microbial identification,” Thorax, vol. 69, no. 8, pp. 776–778, 2014.
M. A. Schechter, M. K. H. Hsieh, L. W. Njoroge et al., “Phosphoproteomic
profiling of human myocardial tissues distinguishes ischemic from non-ischemic
end stage heart failure,” PLoS ONE, vol. 9, no. 8, Article ID e104157, 2014.
E. Hammer, M. Goritzka, S. Ameling et al., “Characterization of the human
myocardial proteome in inflammatory dilatedbcardiomyopathy by label-free
quantitative shotgun proteomics of heart biopsies,” Journal of Proteome Research,
vol. 10, no. 5, pp. 2161–2171, 2011.
Z. Su, H. Zhu, M. Zhang et al., “Salt-induced changes in cardiac phosphoproteome
in a rat model of chronic renal failure,” PLoS ONE, vol. 9, no. 6, Article ID
e100331, 2014.
G. Agnetti, “Modified troponin I as a candidate marker forchronic heart failure: a
top-down perspective,” Circulation:Cardiovascular Genetics, vol. 4, no. 5, pp.
–580, 2011.
G. Agnetti, N. Kaludercic, L. A. Kane et al., “Modulation of mitochondrial
proteome and improved mitochondrial function by biventricular pacing of
dyssynchronous failing hearts,” Circulation: Cardiovascular Genetics, vol. 3, no.
, pp. 78–87, 2010.
P. Zhang, J. A. Kirk, W. Ji et al., “Multiple reaction monitoring to identify site-
specific troponin i phosphorylated residues in the failing human heart,”
Circulation, vol. 126, no. 15, pp. 1828–1837, 2012.
M. S. Willis and C. Patterson, “Proteotoxicity and cardiac dysfunction—
Alzheimer’s disease of the heart?” The New England Journal of Medicine, vol.
, no. 5, pp. 455–464, 2013.
A. Sanbe, H. Osinska, J. E. Saffitz et al., “Desmin-related cardiomyopathy in
transgenic mice: a cardiac amyloidosis,” Proceedings of the National Academy of
Sciences of the Un
